Compare CFLT & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CFLT | CYTK |
|---|---|---|
| Founded | 2014 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 7.6B |
| IPO Year | 2021 | 2004 |
| Metric | CFLT | CYTK |
|---|---|---|
| Price | $30.99 | $63.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 28 | 18 |
| Target Price | $28.73 | ★ $88.50 |
| AVG Volume (30 Days) | ★ 7.0M | 1.8M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.63 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,166,748,000.00 | $13,368,000.00 |
| Revenue This Year | $18.71 | $9.79 |
| Revenue Next Year | $16.90 | $302.66 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.08 | N/A |
| 52 Week Low | $15.64 | $29.31 |
| 52 Week High | $31.00 | $70.98 |
| Indicator | CFLT | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 71.74 | 50.44 |
| Support Level | $30.60 | $59.25 |
| Resistance Level | N/A | $65.27 |
| Average True Range (ATR) | 0.09 | 2.51 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 97.53 | 73.68 |
Confluent Inc provides a data streaming platform that enables customers to connect their applications, systems, and data layers and can be deployed as a fully managed cloud-native software-as-a-service (SaaS) offering. Its products include Confluent Cloud, a self-managed software offering, Confluent Platform, a managed service offering where the raw data resides inside a customer's cloud environment, and WarpStream, among others. Confluent also offers professional services and education services. The company generates revenue from the sale of subscriptions and services. Geographically, it generates a majority of its revenue from its business in the United States and the rest from International markets.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.